Gastroesophageal Cancers | Lunch with the Investigators: Gastroesophageal Cancers

Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Dr Harry H Yoon, including the following topics: Integration of Immune Checkpoint Inhibitors into the Management of HER2-Negative Gastroesophageal (GE) Cancers Introduction (0:00) Adjuvant immunotherapy for GE cancers (1:54) First-line anti-PD-1/PD-L1 antibody-based regimens for metastatic HER2-negative GE cancer (13:11) Future role of novel immunotherapies/checkpoint inhibitors (20:57) Optimal Management of HER2-Positive GE Cancers Selection of first-line therapy for metastatic HER2-positive GE cancer (28:37) Selection of second-line therapy for metastatic HER2-positive GE cancer (36:56) Therapeutic Options for Relapsed/Refractory GE Cancers; Novel Investigational Approaches Selection of second-line therapy for metastatic HER2-negative GE cancer (42:11) Zolbetuximab/chemotherapy as first-line therapy for claudin 18.2-positive metastatic GE cancer (43:09) Use of circulating tumor DNA assays for patients with GE cancers (53:37) CME information and select publications